A recent study from the Humanitas Clinical and Research Center, Rozzano (Milan) 20089, Italy shows that “PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer.” This study was published in the 12 February 2015 issue of the Journal “Cell” [I.F:33] by Drs. Alberto Mantovani , Eduardo Bonavita and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Inflammation-mediated cancers: Metformin, the widely used drug in the treatment of T2DM, increases the expression of oncogenic suppressor PTX3 and inhibits complement-dependent inflammation via down regulation of its target gene. Thus, pharmacological formulations encompassing “Metformin or its analogues” may be used to treat patients suffering from inflammation-mediated tumorigenesis.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for Inflammation-mediated cancers: Metformin increases the expression of oncogenic suppressor PTX3 and inhibits complement-dependent inflammation via down regulation of its target gene, 15/March/2015, 7.33 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com
* Research cooperation
Undisclosed information: How Metformin increases the expression of PTX3